Please login to the form below
Triple-negative breast cancer
This page shows the latest Triple-negative breast cancer news and features for those working in and with pharma, biotech and healthcare.
New trial data for Keytruda in triple-negative breast cancer
triple-negative breast cancer (TNBC) following a recent US Food and Drug Administration (FDA) rejection in this indication. ... TNBC is an aggressive and hard-to-treat subtype of breast cancer, representing around 15% of all breast cancer worldwide,
Latest news
-
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
Envisagenics is also developing a potential preclinical therapeutic in-house – ENV-0205 – for the treatment of triple-negative breast cancer (TNBC). ... This programme came from Envisagenics’ identification of a splicing error that occurs in TNBC,
-
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
in a group of heavily pre-treated triple negative breast cancer (TNBC) patients. ... Triple negative breast cancer is known to be particularly aggressive and fast growing, and after treatment the risk of recurrence is faster and higher than in any other
-
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
triple-negative breast cancer and metastatic urothelial cancer, and the addition of Hepcludex to our portfolio,” said Daniel O’Day, chairman and chief executive officer, Gilead Sciences.
-
FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer
or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1. ... indication”. “People with triple-negative breast cancer have few treatment options, which is why today's committee decision to recognise the importance of this
-
Sanofi pays $160m upfront to acquire Tidal Therapeutics
with Merck &Co’s Keytruda (pembrolizumab) in patients with high-risk melanoma and other cancer types. ... BioNTech also has a number of mRNA-based candidates in development for the treatment of a number of cancer types, including advanced melanoma,
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer
Sanofi pays $160m upfront to acquire Tidal Therapeutics
More from news
Approximately 8 fully matching, plus 70 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic
-
Deal Watch January 2018
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug
-
Pharma deals during February 2014
awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. Financial terms for these deals were ... BATON studies in colorectal cancer and metastatic triple
Cortellis Drugs to Watch in 2020 report
Deal Watch February 2017
Pharma deals during February 2014
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
July 2020: diversity and inclusion in clinical trials round-up
The shocking stats surrounding black women and health outcomes. Alarmingly, although black women are overall less likely to develop breast cancer, they’re 40% more likely to die from it compared ... Black women are at higher risk for a type of
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... 2018; 15(10):599-616. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
July 2020: diversity and inclusion in clinical trials round-up
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Senior Medical Writer
-
Competitive Salary
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Senior Account Executive
-
Competitive Salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Medical Editor
-
Competitive Salary
-
Associate Account Director
-
Competitive Salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
Publications Director
-
Competitive Salary
-
Account Manager
-
Competitive Salary
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
-
Account Management
-
Competitive Salary Offered
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
